Dihydroartemisinin (DHA)‐loaded liposomes enhanced the circulation time of Epirubicin and improved its efficacy in different breast cancer cells by reducing Bcl‐2 activity, promoting Beclin‐1 release, and activating Bax. Here, BAX is linked to breast carcinoma.